Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Lymphoma, Large B-Cell, Diffuse 29Lymphoma, Non-Hodgkin 8Lymphoma, B-Cell 7Lymphoma 5Lymphoma, Follicular 4Recurrence 3Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Dendritic Cell Sarcoma, Interdigitating 2Burkitt Lymphoma 2Neoplasms 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 9glofitamab 4Whole-Body Irradiation 4Rituximab 4fludarabine phosphate 3fludarabine 3Mycophenolic Acid 3Melphalan 3Doxorubicin 3polatuzumab vedotin 2pirtobrutinib 2pembrolizumab 2obinutuzumab 2Tacrolimus 2Sirolimus 2Prednisone 2Busulfan 2zanubrutinib 1venetoclax 1relmacabtagene autoleucel 1pegfilgrastim 1axicabtagene ciloleucel 1Vincristine 1Triamcinolone 1Specimen Handling 1Receptors, Chimeric Antigen 1Prednisolone 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Dendritic Cell Sarcoma, Interdigitating × polatuzumab vedotin × 1 year × Clear all
NCT07231250 2025-11-19

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Sun Yat-sen University

Phase 2 Not yet recruiting
40 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT07034508 2025-06-24

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Not yet recruiting
134 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡